=Flex Pharma (FLKS): FLX-787 Fast Track'd in U.S. for ALS-related muscle cramps

Flex Pharma granted Fast Track Designation for the development of FLX-787 to treat severe muscle cramps in patients with ALS by the FDA; Phase 2 Trials in ALS and CMT to commence in the US this quarter : Co states, "With Phase 2 clinical trials in both ALS and CMT expected to initiate this quarter in the US, FLX-787 will be amongst the most advanced, novel compounds in the clinic for these degenerative neurological diseases. The R&D team is focused on the execution of these new Phase 2 IND studies, as well as completion of the ongoing exploratory Phase 2 spasticity study in MS in Australia. These studies are expected to yield several important data readouts in 2018."